Future of antimycotic therapy

Dermatologic Therapy

Volumn 3, Issue , 1997, Pages 104-111

  Ghannoum, Mahmoud A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000605838     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Pfaller MA, Wenzel R. The impact of changing epidemiology of fungal infections in the 1990's. Eur J Clin Microbiol Infect Dis 1992: 11: 287-291.
2. Richardson MD. Opportunistic and pathogenic fungi. J Antimicrob Chemother 1991: 28 (suppl A): 1-11.
3. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiases in HIV-infected patients. Eur J Clin Microbiol 1993: 12: 911-915 (abstr F63).
4. Baily GG, Perry FM, Denning DW. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994: 8: 787-792.
5. Chavenet P, Lopenz J, Grappin M et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro - in vivo correlation in HIV-infected patients. AIDS 1994: 8: 945-950.
6. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelman E, Trautmann M. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994: 32: 2092-2098.
7. Sangeorzan JA, Bradley SF, Xiaogang H et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994: 97: 339-346.
8. Vuffray A, Durussel C, Boerlin P et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994: 8: 708-709.
9. Diz Dios P, Ocamp Hermidea A, Mirrales Alvarez C, Inglesias Martin I, Otero Varela I. Fluconazole-resistant oral candidosis in HIV-infected patients. AIDS 1995: 9: 809-810.
10. Johnson EM, Warnock DW, Luker J, Porter SB, Scully C. Emergence of azole drug resistance in Candida species form HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995: 35: 103-114.
11. Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1996: 148: 2642-2645.
12. Georgopapadakou NH, Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996: 40: 279-291.
13. Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: a new class of synthetic antifungal agents inhibiting squalene epoxidase. Science 1984: 224: 1239-1241.
14. Ryder NS. Mechanism of action and biochemical selectivity of allylamine antimycotic agents. Ann N Y Acad Sci 1988: 544: 208-230.
15. Ryder NS. Squalene epoxidase as a target for the allylamines. Biochem Soc Trans 1991: 19: 774-777.
16. Georgopapadakou NH, Bertasso A. Effects of squalene epoxidase inhibitors in Candida albicans. Antimicrob Agents Chemother 1992: 36: 1779-1781.
17. Ryder NS. Selective inhibition of squalene epoxidation by allylamine antimycotic agents. In: Nombela C, ed. Microbial cell wall synthesis and autolysis. Amsterdam: Elsevier Science Publishers; 1984: 313-321.
18. Roberts DT. Treatment of fungal infections of skin and nail. Presented at Clinical Dermatology 2000, An International Congress, Abstract 32. Vancouver, Canada, 1996.
19. Fothergill AW, Leitner I, Meingassner JG, Ryder NS, Rinaldi MG. Combination antifungal susceptibility testing of terbinafine and the triazoles fluconazole and itraconazole. Abstract E53. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans), 1996.
20. Rodero L, Vitale R, Hochenfellner F, Canteros C, Davel G. In vitro activity of terbinafine in combination with triazole drugs against fluconazole resistant Candida species. Abstract E56. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans), 1996.
21. Ryder NS, Wagner S, Leitner I. In vitro activity of terbinafine against Candida and other yeasts by the NCCLS method. Abstract E55. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans), 1996.
22. Parmegiani R, Cacciapuoti A, Loebenberg D et al. In vitro activity of SCH 56592. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, An Annual Meeting of the American Society for Microbiology, 1995: 123.
23. Perfect JR, Schell WA. In vitro efficacy of the azole, SCH 56592, compared to amphotericin B, fluconazole, and itraconazole versus Cryptococcus neoformans. Abstract F64. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, An Annual Meeting of the American Society for Microbiology, 1995: 124.
24. Sugar AM, Liu XP. In vitro activity of SCH against Blastomyces dermatitidis (Bd). Abstract F65. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, An Annual Meeting of the American Society for Microbiology, 1995: 124.
25. Stevens DA, Devine MJ, Martinez M, Aristizabal B. In vitro antifungal activity of novel azole derivatives with a morpholine ring. Abstract F85. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, An Annual Meeting of the American Society for Microbiology, 1995: 127.
26. Hata K, Ueno J, Miki H et al. ER-30346, a novel antifungal triazole. III. In vitro activity and the mode of action. Abstract F92. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, An Annual Meeting of the American Society for Microbiology, 1995: 129.
27. Nakamura T, Sakai R, Sonada J, Katoh T, Kaneko T, Horie T. ER-30346, a novel antifungal triazole. IV. Pharmacokinetic and toxicological studies in mice, rats, and dogs. Abstract F94. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, An Annual Meeting of the American Society for Microbiology, 1995: 129.
28. Itoh K, Okonagi K, Tasaka A et al. TAK 187, a new antifungal triazole: synthesis and antifungal activity. Abstract F74. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996: 112.
29. Yokoyama K, Wang L, Miyaji M. SSY726, a new triazole antifungal agent: in vitro and in vivo evaluation. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996: 112.
30. Tatsumi Y, Yokoo M, Arika T, Ogura H, Nagal K, Naito T. Therapeutic efficacy of KP-103, a novel topical antifungal triazole, on experimental superficial mycosis. Abstract F80. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996: 113.
31. Law D, Denning DW. In vitro activity of Schering 56592, compared with fluconazole and intraconazole against Candida spp. Abstract F88. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996: 115.
32. Fothergill AW, Sutton DA, Rinaldi MG. An in vitro head-to-head comparison of Schering 5692, amphotericin V, fluconazole, and intraconazole against a spectrum of filamentous fungi. Abstract F89. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996: 115.
33. Munayyer H, Shaw KJ, Hare RS et al. SCH 56592 is a potent inhibitor of sterol C-14 demethylation in fungi. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996: 115.
34. Sanati H, Belanger PH, Fratti RA, Ghannoum MA. Effect of voriconazole (UK-109, 496) on the sterol biosynthesis of Candida albicans and Candida krusei. Abstract C65. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996.
35. Belanger PH, Ibrahim AS, Sanati H, Ghannoum MA. The new triazole, voriconazole (UK-109,496) inhibits the growth of Candida krusei and its interaction with endothelial cells. In: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996.
36. S) Candida albicans. Abstract F74. Abstracts of the 96th General Meeting of the American Society for Microbiology, 1996.
37. S) Candida albicans strains. Abstract F75. Abstracts of the 96th General Meeting of the American Society for Microbiology, 1996.
38. Fratti RA, Belanger PH, Sanati H, Ibrahim AS, Ghannoum MA. The effect of the new triazole, UK-109496 on the interactions between Candida albicans and endothelial cells in vitro. Abstract F76. Abstracts of the 96th General Meeting of the American Society for Microbiology, 1996.
39. Hitchcock CA, Whittle PT. Chemistry and mode of action of fluconazole. In: Rippon JW, Fromtling RA, ed. Cutaneous antifungal agents: selected compounds in clinical practice and development. New York: Marcel Dekker, 1993.
40. Vanden Bossche H, Marichal P, Le Jeunes L, Coence M, Gorrens J, Cools W. Effects of itraconazole on cytochrome P-450-dependent 14-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 1993: 37: 2101-2105.
41. Ghannoum MA, Spellberg B, Ibrahim AS et al. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother 1994: 38: 2029-2033.
42. Pancaldi S, Dall Oliio G, Poli F, Fasulo MP. Stimulation of autophagic activity in blastospores of Candida albicans exposed in vitro to fluconazole. Microbios 1994: 80: 55-61.
43. Pesti M, Campbell JM, Peberdy IF. Alterations of ergosterol content and chitin synthase activity in Candida albicans. Curr Microbiol 1981: 5: 187-190.
44. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995: 39: 1907-1912.
45. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990: 12: 308-329.
46. Wiebe VJ, DeGregorio MW. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Infect Dis 1988: 10: 1097-1011.
47. Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K. Treatment of hepatosplenic candidiasis with liposomal amphotericin. Br Clin Oncol 1987: 5: 310-317.
48. Cheng JT, Witty RT, Robinson RR, Yarger WE. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int 1982: 22: 626-633.
49. Juliano RL, Grant CWM, Barber KR, Kalp MA. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987: 31: 1-11.
50. Payne NI, Cosgrove RF, Green AP, Liu L. In vivo studies of amphotericin B liposomes derived from proliposomes; effect of formulation on toxicity and tissue disposition of the drug in mice. J Pharm Pharmacol 1987: 39: 24-28.
51. Proffitt RT, Lee MJ, McAndrew BJ, Adler-Moore J, Fratti R, Ghannoum MA. In vitro interaction of ambisome with red blood cells and endothelial cells. Presented at Focus on Fungal Infections 5, San Francisco. March 9-10, 1995.
52. Wallace TL, Paeznick V, Cassum PA, Anaissie E. Nyotran (Liposomal nystatin) against disseminated Aspergillus fumigatus in neutropenic mice. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996: 31.
53. Sullivan PA, Chiew YY, Molloy C, Templeton MD, Shepard MG. An analysis of the metabolism and cell wall composition of Candida albicans during germ tube formation. Can J Biochem 1983: 29: 1514-1525.
54. Cassone A, Mason RE, Kerridge D. Lysis of growing yeast form cells of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. J Gen Microbiol 1979: 110: 339-349.
55. Poulain D, Tronchin Dubremetz JF, Biguet J. Ultrastructure of the cell wall of Candida albicans blastospores: study of the constitutive layers by the use of a cytochemical technique revealing polysaccharides. Ann Microbiol 1978: 129A: 141-153.
56. Surarit R, Gopal PK, Shepard MG. Evidence for a glycosidic linkage between chitin and glycan in the cell wall of Candida albicans. J Gen Microbiol 1988: 134: 1723-1730.
57. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993: 6: 1-21.
58. Endo A, Kakiki K, Missato T. Mechanism of action of the antifungal agent polyoxin. J Bacteriol 1970: 104: 189-196.
59. Endo A, Missato T. Polyoxin D, a competitive inhibitor of UDP-N acetylglucosaminyltransferase in Neurospora crassa. Biochem Biophys Res Commun 1969: 37: 718-722.
60. Muller H, Further R, Zahner H, Rast DM. Metabolic products of microorganisms. 203. Inhibition of chitosomal chitin synthetase and growth of Mucor rouxil by nikkomycin Z, nikkomycin X and polyoxin A: a comparison. Arch Microbiol 1981: 130: 195-197.
61. Flores ME, Hector RF. In vitro activity of the antifungal nikkomycin Z (SP-920704) in combination with fluconazole or itraconazole vs. yeasts. Abstract F190. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1996
62. Cassone A, Mason RE, Kerridge D. Lysis of growing yeast form cells of Candida albicans by echinocandin: a cytological study. Sabouraudia 1981: 19: 97-110.
63. Tkacz JS. Glycan biosynthesis in fungi and its inhibition. In: Sutcliffe J, Georgopapadakou NH, ed., Emerging targets in antibacterial and antifungal chemotherapy. New York: Chapman & Hall, 1996: 495-523.
64. Walsh TJ, Lee JW, Kelly P et al. The antifungal effects of the nonlinear pharmacokinetics of cilofungin. A 1.3 B-glycan synthase inhibitor, during continuous vs. intermittent infusion of cilofungin in the treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother 1991: 35: 1371-1328.
65. Doebbeling BN, Fine BD Jr, Pfaller MA, Sheetz CT, Stokes JB, Wenzel RP. Abstract 583. 30th Interscience Conference Antimicrobial Agents and Chemotherapy, 1990.
66. Balkovec JM, Black RM, Hammond ML et al. Synthesis, stability, and biological evaluation of water-soluble pro-drugs of a new echinocandin lipeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP). J Med Chem 1992: 35: 194-198.
67. Van Middlesworth F, Omstead MN, Schmatz D et al. A new member of the papulacandin family of B 1,3 D-glycan synthesis inhibitors. I. Fermentation, isolation, and biological activity. J Antibiot 1991: 44: 45-51.
68. Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States - 1980-1989. Am J Med 1991: suppl. 3B: 86S-90S.
69. Polak A. Combination therapy for systemic mycosis. Infection 1996: 17: 203-209.
70. Ghannoum MA, Fu Y, Ibrahim AS et al. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1989: 39: 2459-2465.
71. Sanati H, Ramos CF, Bayer AS, Ghannoum MA. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic murine and infective endocarditis rabbit models: lack of in vivo antagonism. Submitted.
72. Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive and candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995: 39: 598-601.
73. Bolard, Milhaud. Interaction of the anti-Candida amphotericin B (and other polyene antibiotics) with lipids. In: Prasad R, Ghannoum MA, ed. Lipids of pathogenic fungi. Boca Raton, FL: CRC Press, 1996: 253-274.
74. Perfect JR. Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob Agents Chemother 1996: 40: 1577-1588.
75. Lanyi JK, Plachy WZ, Kates M. Lipid interactions in membranes of extremely halophilic bacteria. II. Modification of the bilayer structure by squalene. Biochemistry 1974: 4914-1920.